Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy
- PMID: 11895922
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy
Abstract
Purpose: Potential causes of drug resistance in solid tumors include genetically determined factors expressed in individual cells and those related to the solid tumor environment. Important among the latter is the requirement for drugs to penetrate into tumor tissue and to achieve a lethal concentration in all of the tumor cells. The present study was designed to characterize further the multicellular layer (MCL) method for studying drug penetration through tumor tissue and to provide information about tissue penetration for drugs used commonly in the treatment of human cancer.
Experimental design: EMT-6 mouse mammary and MGH-U1 human bladder cancer cells were grown on collagen-coated semiporous Teflon membranes to form MCLs approximately 200 microm thick. The properties of MCLs were compared with those of tumors grown in mice from the same cells. The penetration of drugs through the MCL was evaluated by using radiolabeled drugs or analytical methods.
Results: The MCL developed an extracellular matrix containing both laminin and collagen, although there were some differences in expression of extracellular matrix proteins. Electron microscopy showed rare desmosomes in both MCL and tumors. The penetration of cisplatin, etoposide, gemcitabine, paclitaxel, and vinblastine through tissue in the MCL was slow compared with penetration through the Teflon support membrane alone.
Conclusions: Our results suggest limited ability of anticancer drugs to reach tumor cells that are distant from blood vessels. The limited penetration of anticancer drugs through tumor tissue may be an important cause of clinical resistance of solid tumors to chemotherapy.
Similar articles
-
Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors.Clin Cancer Res. 1999 Jun;5(6):1583-6. Clin Cancer Res. 1999. PMID: 10389947
-
Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells.Oncol Rep. 2011 Mar;25(3):863-70. doi: 10.3892/or.2011.1138. Epub 2011 Jan 10. Oncol Rep. 2011. PMID: 21225235
-
The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells.Cancer Res. 2006 Jan 15;66(2):1033-9. doi: 10.1158/0008-5472.CAN-05-3077. Cancer Res. 2006. PMID: 16424039
-
Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.Expert Opin Drug Metab Toxicol. 2011 Dec;7(12):1601-12. doi: 10.1517/17425255.2011.625012. Epub 2011 Sep 28. Expert Opin Drug Metab Toxicol. 2011. PMID: 21955161 Review.
-
Current and future perspectives in advanced bladder cancer: is there a new standard?Semin Oncol. 2002 Feb;29(1 Suppl 3):3-14. doi: 10.1053/sonc.2002.30750. Semin Oncol. 2002. PMID: 11894002 Review.
Cited by
-
Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor.Cell Chem Biol. 2021 Sep 16;28(9):1258-1270.e13. doi: 10.1016/j.chembiol.2021.04.004. Epub 2021 Apr 27. Cell Chem Biol. 2021. PMID: 33910023 Free PMC article.
-
Multicellular tumor spheroids for evaluation of cytotoxicity and tumor growth inhibitory effects of nanomedicines in vitro: a comparison of docetaxel-loaded block copolymer micelles and Taxotere®.PLoS One. 2013 Apr 23;8(4):e62630. doi: 10.1371/journal.pone.0062630. Print 2013. PLoS One. 2013. PMID: 23626842 Free PMC article.
-
Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.Int J Mol Sci. 2021 May 7;22(9):4975. doi: 10.3390/ijms22094975. Int J Mol Sci. 2021. PMID: 34067057 Free PMC article. Review.
-
Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy.Front Pharmacol. 2013 Jun 25;4:68. doi: 10.3389/fphar.2013.00068. eCollection 2013. Front Pharmacol. 2013. PMID: 23805101 Free PMC article.
-
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.Sci Signal. 2013 Aug 6;6(287):ra66. doi: 10.1126/scisignal.2004155. Sci Signal. 2013. PMID: 23921085 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical